Elkfork Partners’s Enanta Pharmaceuticals ENTA Stock Holding History

Elkfork Partners’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$200K	Buy	3,332 +272	+9%	+$20.2K	﹤0.01%	826
2019 Q2	$258K	Hold	3,060	–	–	0.01%	760
2019 Q1	$292K	Hold	3,060	–	–	0.01%	709
2018 Q4	$217K	Hold	3,060	–	–	0.01%	744
2018 Q3	$261K	Buy	3,060 +952	+45%	+$95.4K	0.01%	780
2018 Q2	$244K	Hold	2,108	–	–	0.01%	733
2018 Q1	$171K	Buy	+2,108	New	+$162K	﹤0.01%	831
2017 Q1	–	Sell	-680	Closed	-$23K	–	1005
2016 Q4	$23K	Buy	+680	New	+$19.5K	﹤0.01%	962

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Elkfork Partners's ENTA Position: Q3 2019 in Review

Elkfork Partners increased its Enanta Pharmaceuticals (ENTA) stake by 8.9% in Q3 2019, buying an estimated $20.2K and bringing the position to 3,332 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #826.

Elkfork Partners first reported a position in ENTA in Q4 2016 and has held it in 8 quarters since. The position peaked at $292K in Q1 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Elkfork Partners held 3,332 shares of Enanta Pharmaceuticals worth $200K as of Q3 2019.
Elkfork Partners bought 272 Enanta Pharmaceuticals shares in Q3 2019, an estimated $20.2K.
Enanta Pharmaceuticals made up ﹤0.01% of Elkfork Partners's portfolio in Q3 2019, its #826 holding.
Elkfork Partners first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 8 quarters since.
Elkfork Partners's Enanta Pharmaceuticals position peaked at $292K in Q1 2019.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.